Serious adverse events with novel beta-lactam/beta-lactamase inhibitor combinations: a large-scale pharmacovigilance analysis

The purpose of this study is to characterize adverse events (AEs) of clinical interest reported with ceftolozane-tazobactam and ceftazidime-avibactam, as an aid in monitoring patients affected by severe multidrug-resistant Gram-negative infections. We queried the worldwide FDA Adverse Event Reportin...

Descripción completa

Detalles Bibliográficos
Autores principales: Gatti, Milo, Raschi, Emanuel, De Ponti, Fabrizio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8139903/
https://www.ncbi.nlm.nih.gov/pubmed/33415492
http://dx.doi.org/10.1007/s10096-020-04149-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8139903/
https://www.ncbi.nlm.nih.gov/pubmed/33415492
http://dx.doi.org/10.1007/s10096-020-04149-3

Ejemplares similares